ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

Rhea-AI Summary

ARS Pharmaceuticals (Nasdaq: SPRY), a biopharmaceutical company focused on anaphylaxis prevention, will host a conference call and webcast to discuss its Q2 2025 financial results on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET.

Participants can register for the event to receive dial-in information. The webcast and presentation slides will be accessible through the Events & Presentations page on the company's website, with a replay available for 30 days after the event.

News Market Reaction – SPRY

+1.16%

1 alert

+1.16% News Effect

On the day this news was published, SPRY gained 1.16%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its second quarter 2025 financial results and business highlights.

Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy^® (trade name EURneffy^® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.

Investor Contact:
Justin Chakma, ARS Pharma
justinc@ars-pharma.com

Monique Allaire, THRUST
monique@thrustsc.com

Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
615.414.8668

FAQ

When is ARS Pharmaceuticals (SPRY) Q2 2025 earnings call?

ARS Pharmaceuticals will host its Q2 2025 earnings call on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET.

How can I access ARS Pharmaceuticals (SPRY) Q2 2025 earnings webcast?

Investors can access the webcast through the Events & Presentations page in the Investors & Media section of the company's website. Registration is required for conference call dial-in information.

How long will ARS Pharmaceuticals Q2 2025 earnings webcast be available?

The webcast replay will be available for 30 days following the event.

What does ARS Pharmaceuticals (SPRY) do?

ARS Pharmaceuticals is a biopharmaceutical company focused on empowering at-risk patients and caregivers to better protect patients from allergic reactions that could lead to anaphylaxis.